Virtu Financial’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-20,853
| Closed | -$1.13M | – | 1670 |
|
|
2025
Q4 | $1.13M | Sell |
20,853
-41,416
| -67% | -$1.99M | 0.04% | 311 |
|
|
2025
Q3 | $2.81M | Buy |
62,269
+41,093
| +194% | +$1.92M | 0.16% | 127 |
|
|
2025
Q2 | $980K | Buy |
+21,176
| New | +$1.04M | 0.05% | 340 |
|
|
2025
Q1 | – | Sell |
-45,141
| Closed | -$2.55M | – | 1391 |
|
|
2024
Q4 | $2.55M | Buy |
+45,141
| New | +$2.52M | 0.14% | 131 |
|
|
2024
Q3 | – | Sell |
-13,606
| Closed | -$565K | – | 1396 |
|
|
2024
Q2 | $565K | Buy |
13,606
+6,985
| +105% | +$313K | 0.04% | 416 |
|
|
2024
Q1 | $359K | Sell |
6,621
-70,571
| -91% | -$3.59M | 0.03% | 539 |
|
|
2023
Q4 | $3.96M | Buy |
+77,192
| New | +$4.05M | 0.31% | 41 |
|
|
2023
Q2 | – | Sell |
-4,100
| Closed | -$284K | – | 1535 |
|
|
2023
Q1 | $284K | Sell |
4,100
-29,396
| -88% | -$2.07M | 0.03% | 568 |
|
|
2022
Q4 | $2.41M | Buy |
+33,496
| New | +$2.53M | 0.32% | 46 |
|
|
2022
Q3 | – | Sell |
-17,190
| Closed | -$1.32M | – | 1746 |
|
|
2022
Q2 | $1.32M | Buy |
+17,190
| New | +$1.31M | 0.11% | 165 |
|
|
2021
Q4 | – | Sell |
-79,390
| Closed | -$4.7M | – | 1725 |
|
|
2021
Q3 | $4.7M | Buy |
+79,390
| New | +$5.23M | 0.41% | 25 |
|
|
2021
Q1 | – | Sell |
-21,900
| Closed | -$1.36M | – | 1611 |
|
|
2020
Q4 | $1.36M | Buy |
+21,900
| New | +$1.35M | 0.15% | 173 |
|
|
2019
Q4 | $1.13M | Sell |
17,648
-7,608
| -30% | -$436K | 0.11% | 196 |
|
|
2019
Q3 | $1.28M | Buy |
25,256
+1,969
| +8% | +$92.5K | 0.1% | 216 |
|
|
2019
Q2 | $1.06M | Sell |
23,287
-10,950
| -32% | -$510K | 0.06% | 276 |
|
|
2019
Q1 | $1.63M | Buy |
+34,237
| New | +$1.71M | 0.09% | 182 |
|
|
2018
Q4 | – | Sell |
-4,029
| Closed | -$250K | – | 1568 |
|
|
2018
Q3 | $250K | Sell |
4,029
-12,554
| -76% | -$745K | 0.02% | 953 |
|
|
2018
Q2 | $918K | Buy |
+16,583
| New | +$896K | 0.06% | 441 |
|
|
2018
Q1 | – | Sell |
-24,911
| Closed | -$1.53M | – | 1974 |
|
|
2017
Q4 | $1.53M | Buy |
+24,911
| New | +$1.56M | 0.08% | 276 |
|
|
2017
Q2 | – | Sell |
-5,566
| Closed | -$303K | – | 389 |
|
|
2017
Q1 | $303K | Sell |
5,566
-12,331
| -69% | -$676K | 0.03% | 298 |
|
|
2016
Q4 | $1.05M | Buy |
+17,897
| New | +$978K | 0.11% | 146 |
|
|
2016
Q1 | – | Sell |
-5,335
| Closed | -$367K | – | 403 |
|
|
2015
Q4 | $367K | Buy |
+5,335
| New | +$353K | 0.05% | 263 |
|
Other funds holding BMY
VCM
VPM
Virtu Financial's BMY Position: Q1 2026 in Review
Virtu Financial sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 20,853 shares — an estimated $1.13M sold.
Virtu Financial first reported a position in BMY in Q4 2015 and held it in 22 quarters. The position peaked at $4.7M in Q3 2021. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Virtu Financial reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- Virtu Financial sold 20,853 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.13M.
- Virtu Financial first reported a position in Bristol-Myers Squibb in Q4 2015 and held it in 22 quarters.
- Virtu Financial's Bristol-Myers Squibb position peaked at $4.7M in Q3 2021.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.